Reich Lisa, Gatzke Florian, Rauchfuss Steffen, Roth Stefanie, Miesbach Wolfgang
Medical Clinic 2, University Hospital Frankfurt, Germany.
Res Pract Thromb Haemost. 2025 Feb 27;9(2):102707. doi: 10.1016/j.rpth.2025.102707. eCollection 2025 Feb.
Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against factor (F)VIII (FVIII), potentially leading to life-threatening bleeding. While predictors for remission have been analyzed, data on recurrence is lacking.
This study investigated predictors of AHA recurrence in 41 patients. Patients were divided into 2 groups: those with recurrence ( = 18) and those in stable long-term remission ( = 23) with at least 1 year of follow-up.
All relapses occurred within 1 year of initial remission. The median follow-up period was 3.8 years (IQR, 1.8-6.4) for all included patients. Multivariate Cox regression analysis revealed that initial FVIII activity <1 IU/dL and failure to achieve initial complete remission (CR) were significant predictors of relapse. Kaplan-Meier curves showed significantly different relapse-free survival rates for patients with initial FVIII activity <1 IU/dL vs ≥1 IU/dL (χ[1] = 5.950, = .015), and for those achieving initial CR vs partial remission (χ[1] = 6.570, = .010).Other factors such as inhibitor titer, gender, age, World Health Organization scale, underlying disorder, controlled disorder, initial immunosuppressive therapy, immunosuppressive therapy escalation, and partial remission at day 21 showed no significant relation to recurrences. Overall survival did not differ significantly between relapsing and nonrelapsing patients (χ[1] = .896, = .344).
Initial FVIII <1 IU/dL and failure to achieve initial CR are identified as risk factors for recurrence in AHA. Patients with these characteristics should be closely monitored for at least 1 year after initial remission due to increased recurrence risk.
获得性血友病A(AHA)是一种由抗凝血因子(F)VIII(FVIII)自身抗体引起的罕见自身免疫性疾病,可能导致危及生命的出血。虽然已经分析了缓解的预测因素,但缺乏关于复发的数据。
本研究调查了41例AHA患者复发的预测因素。患者分为两组:复发组(n = 18)和稳定长期缓解组(n = 23),随访至少1年。
所有复发均发生在初次缓解后的1年内。所有纳入患者的中位随访期为3.8年(四分位间距,1.8 - 6.4)。多因素Cox回归分析显示,初始FVIII活性<1 IU/dL和未实现初次完全缓解(CR)是复发的重要预测因素。Kaplan-Meier曲线显示,初始FVIII活性<1 IU/dL与≥1 IU/dL的患者无复发生存率有显著差异(χ[1]=5.950,P = 0.015),实现初次CR与部分缓解的患者无复发生存率有显著差异(χ[1]=6.570,P = 0.010)。其他因素,如抑制物滴度、性别、年龄、世界卫生组织分级、基础疾病、可控疾病、初始免疫抑制治疗、免疫抑制治疗升级以及第21天的部分缓解与复发无显著关系。复发患者和未复发患者的总生存率无显著差异(χ[1]=0.896,P = 0.344)。
初始FVIII<1 IU/dL和未实现初次CR被确定为AHA复发的危险因素。由于复发风险增加,具有这些特征的患者在初次缓解后应密切监测至少1年。